Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer

Who is this study for? Patients with ovarian cancer
What treatments are being studied? [11C]PiB and 18F-labeled DPA-714 PET scan
Status: Not yet recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This clinical study will use the small molecule translocator protein (TSPO) ligand, 18F-labeled DPA- 714, to visualize and quantify neuroinflammation in treatment naivete women with stage 1-4 newly diagnosed ovarian cancer (without brain metastases) prior to starting neoadjuvant chemotherapy treatment (baseline) and within a month of completing first 6 cycles of cytotoxic chemotherapy treatment (follow-up). In addition, we will use the well-characterized small molecule PET(Positron Emission Tomography) tracer, 11C-labeled Pittsburgh compound B (PiB) to visualize and quantify the regional brain distribution of pathological amyloid deposition at baseline only. The brain amyloid PET and MRI data acquired through this study will be correlated with cognitive test data, clinical data, genetic testing, and biospecimens collected in this study.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 50
Healthy Volunteers: No
View:

• 50 years of age or older

• Female gender

• Newly diagnosed treatment naïve women with stage III/IV epithelial ovarian cancer (without known brain metastases).

• High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.

• English is primary language

• Planned neoadjuvant chemotherapy with platinum and taxane drugs

Locations
United States
Alabama
The University of Alabama at Birmingham
Birmingham
Contact Information
Primary
Jonathan McConathy, MD, PhD
jmcconathy@uabmc.edu
205-996-7115
Backup
April Riddle, BS RT
ariddle@uabmc.edu
205-934-6504
Time Frame
Start Date: June 2025
Estimated Completion Date: August 2026
Participants
Target number of participants: 20
Treatments
Experimental: treatment naivete women with stage 1-4 newly diagnosed ovarian
Authors
Margaret Liang, Charles Leath, John Straughn, Jonathan McConathy, Kenneth Kim, Pradeep Bhambhvani, Kerri Bevis, Warner Huh, Kristen Tribel (Gerstenecker), Gagandeep Choudhary, Charlotte Denise Jeffers, L. Burt Nabors, Suzanne Lapi
Related Therapeutic Areas
Sponsors
Leads: University of Alabama at Birmingham

This content was sourced from clinicaltrials.gov

Similar Clinical Trials